WHO ICTRP trial
Study of high-dose sunitinib in patients with solid tumors.
NL-OMON20988 · Overview of Medical Research in the Netherlands (NL-OMON) · Recruiting
Key facts
| Trial ID | NL-OMON20988 |
|---|---|
| Public title | Study of high-dose sunitinib in patients with solid tumors. |
| Scientific title | A phase I study of high-dose, intermittent sunitinib in patients with solid tumors. |
| Primary sponsor | VU Medical Center Amsterdam |
| Registry | Overview of Medical Research in the Netherlands (NL-OMON) |
| Recruitment status | Recruiting |
| Study type | Interventional |
| Conditions | Adult patients with locally advanced or metastatic solid tumors for which no standard therapy exists. |
| Interventions | Sunitinib once every week or once every 2 weeks, at a starting dose of 200 mg |
| Registration date | Sep 10, 2013 |
| Target size | 40 |
| Secondary IDs | NL3995;NTR4167;METC VUmedical Center : 2013/75;ISRCTN wordt niet meer aangevraagd. |
| Registry page | onderzoekmetmensen.nl |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: